Related Experiment Video
Updated: Jul 17, 2025
Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis
Published on: March 31, 2015
Functional Genomics of Novel Rhabdomyosarcoma Fusion-Oncogenes Using Zebrafish
Matthew R Kent1, Katherine Silvius1, Jack Kucinski1,2
1Center for Childhood Cancer & Blood Diseases, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, USA.
Abstract:
Clinical sequencing efforts continue to identify novel putative oncogenes with limited strategies to perform functional validation in vivo and study their role in tumorigenesis. Here, we present a pipeline for fusion-driven rhabdomyosarcoma (RMS) in vivo modeling using transgenic zebrafish systems. This strategy originates with novel fusion-oncogenes identified from patient samples that require functional validation in vertebrate systems, integrating these genes into the zebrafish genome, and then characterizing that they indeed drive rhabdomyosarcoma tumor formation. In this scenario, the human form of the fusion-oncogene is inserted into the zebrafish genome to understand if it is an oncogene, and if so, the underlying mechanisms of tumorigenesis. This approach has been successful in our models of infantile rhabdomyosarcoma and alveolar rhabdomyosarcoma, both driven by respective fusion-oncogenes, VGLL2-NCOA2 and PAX3-FOXO1. Our described zebrafish platform is a rapid method to understand the impact of fusion-oncogene activity, divergent and shared fusion-oncogene biology, and whether any analyzed pathways converge for potential clinically actionable targets.
Insights
Researchers developed a zebrafish model to test new cancer-causing genes (oncogenes) found in rhabdomyosarcoma (RMS). This rapid system validates fusion-oncogenes and explores therapeutic targets.
Area of Science:
- Oncology
- Genetics
- Zebrafish Modeling
Background:
- Clinical sequencing identifies novel oncogenes, but in vivo functional validation remains challenging.
- Rhabdomyosarcoma (RMS) tumorigenesis is often driven by fusion-oncogenes requiring robust experimental models.
- Understanding fusion-oncogene mechanisms is crucial for developing targeted therapies.
Purpose of the Study:
- To present a pipeline for in vivo modeling of fusion-driven rhabdomyosarcoma using transgenic zebrafish.
- To functionally validate novel fusion-oncogenes identified from patient samples.
- To investigate the mechanisms of tumorigenesis driven by specific fusion-oncogenes.
Main Methods:
- Integration of human fusion-oncogenes identified from RMS patient samples into the zebrafish genome.
- Development of transgenic zebrafish systems for in vivo modeling.
- Characterization of tumor formation driven by the integrated fusion-oncogenes.
Main Results:
- Successful establishment of zebrafish models for infantile and alveolar rhabdomyosarcoma.
- Demonstrated that fusion-oncogenes like VGLL2-NCOA2 and PAX3-FOXO1 drive RMS tumor formation in vivo.
- The zebrafish platform enables rapid assessment of fusion-oncogene impact and shared/divergent biology.
Conclusions:
- The described zebrafish platform offers a rapid and effective method for in vivo functional validation of fusion-oncogenes in rhabdomyosarcoma.
- This model facilitates the study of fusion-oncogene biology and identification of convergent pathways for potential therapeutic targets.
- This approach advances the understanding and treatment strategies for fusion-driven RMS.
